Gujarat Terce Laboratories Limited
BSE: GUJTERC
Prev Close
38.31
Open Price
41.63
Volume
1,223
Today Low / High
38 / 41.63
52 WK Low / High
37.2 / 73
Range
37 - 40
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 38.53, reflecting a change of 0.22 (0.57426%). The expected target range on the BSE is 37 - 40. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Gujarat Terce Laboratories Limited Graph
Gujarat Terce Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Gujarat Terce Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 38.53, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 38.53 | 38.92 | 35.02 - 42.81 |
| 39.30 | 31.44 - 47.16 | ||
| 39.69 | 27.78 - 51.59 | ||
| Bearish Scenario | 38.53 | 38.14 | 34.33 - 41.96 |
| 37.76 | 30.21 - 45.31 | ||
| 37.37 | 26.16 - 48.59 |
Overview of Gujarat Terce Laboratories Limited
ISIN
INE499G01013
Industry
Medical - Pharmaceuticals
Vol.Avg
3,534
Market Cap
311,262,435
Last Dividend
0
Official Website
IPO Date
2024-12-30
DCF Diff
69.17
DCF
-29
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 50.20 Cr | 35.48 Cr | 14.71 Cr | 0.2931 | 0.00 Cr | 16.38 Cr | 3.50 Cr | -0.98 Cr | -1.32 | 4.19 Cr | -0.0195 |
| 2024-03-31 | 47.97 Cr | 33.83 Cr | 14.14 Cr | 0.2948 | 0.00 Cr | 1.07 Cr | 0.93 Cr | 0.24 Cr | 0.33 | 1.54 Cr | 0.0051 |
| 2023-03-31 | 46.78 Cr | 40.51 Cr | 6.27 Cr | 0.1341 | 0.00 Cr | 14.98 Cr | -2.08 Cr | -1.67 Cr | -2.25 | -1.81 Cr | -0.0357 |
| 2022-03-31 | 40.13 Cr | 31.66 Cr | 8.47 Cr | 0.2111 | 0.00 Cr | 0.77 Cr | 0.85 Cr | 0.87 Cr | 1.18 | 1.42 Cr | 0.0217 |
| 2021-03-31 | 25.18 Cr | 23.19 Cr | 1.98 Cr | 0.0788 | 0.00 Cr | 0.73 Cr | -2.75 Cr | -2.52 Cr | -3.40 | -1.97 Cr | -0.1001 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.78 Cr | 22.83 Cr | 16.35 Cr | 6.4775 Cr | 0.94 Cr | 0.16 Cr | 3.68 Cr | 3.65 Cr | 0.00 Cr | 0.00 Cr | 2.24 Cr | 12.6431 Cr |
| 2024-03-31 | 0.09 Cr | 23.27 Cr | 16.17 Cr | 7.1061 Cr | 3.87 Cr | 3.78 Cr | 4.17 Cr | 3.69 Cr | 0.00 Cr | 1.38 Cr | 0.27 Cr | 12.1416 Cr |
| 2023-03-31 | 2.03 Cr | 28.72 Cr | 21.86 Cr | 6.8627 Cr | 7.27 Cr | 5.24 Cr | 4.54 Cr | 3.99 Cr | 0.06 Cr | 1.90 Cr | 2.32 Cr | 16.6080 Cr |
| 2022-03-31 | 0.01 Cr | 27.56 Cr | 19.03 Cr | 8.5343 Cr | 6.67 Cr | 6.66 Cr | 6.46 Cr | 4.29 Cr | 0.09 Cr | 1.93 Cr | 2.68 Cr | 13.2136 Cr |
| 2021-03-31 | 1.29 Cr | 21.80 Cr | 14.14 Cr | 7.6620 Cr | 4.74 Cr | 3.45 Cr | 3.74 Cr | 2.45 Cr | 0.00 Cr | 0.87 Cr | 2.62 Cr | 11.6418 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2.8997 Cr | 0.1993 Cr | -2.4096 Cr | 0.0000 Cr | 0.6894 Cr | 0.7794 Cr | 0.0000 Cr | -0.9787 Cr | -2.9247 Cr | 0.0000 Cr | 0.2507 Cr |
| 2024-03-31 | 2.5997 Cr | -0.4579 Cr | -4.0816 Cr | 2.5260 Cr | -1.9398 Cr | 0.0901 Cr | -0.0737 Cr | 0.2434 Cr | -3.4056 Cr | 0.0000 Cr | 0.4449 Cr |
| 2023-03-31 | -0.3402 Cr | 0.2606 Cr | 0.6003 Cr | -0.4033 Cr | 2.0207 Cr | 2.0299 Cr | -0.0631 Cr | -1.6716 Cr | 0.6003 Cr | 0.0000 Cr | 2.0011 Cr |
| 2022-03-31 | -0.4433 Cr | -0.8677 Cr | 1.5337 Cr | -2.6709 Cr | 0.2228 Cr | 0.0092 Cr | -2.1141 Cr | 0.8723 Cr | 1.9346 Cr | 0.0000 Cr | -2.6915 Cr |
| 2021-03-31 | -0.4133 Cr | -0.4625 Cr | 2.1205 Cr | -0.9177 Cr | 1.2447 Cr | 1.2864 Cr | -0.5044 Cr | -2.5202 Cr | 2.1413 Cr | 0.0000 Cr | -0.3063 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 12.29 Cr | 8.63 Cr | 3.66 Cr | 0.2978 | 1.04 Cr | 0.76 Cr | 0.98 | 1.26 Cr | 0.0619 |
| 2025-09-30 | 12.93 Cr | 8.58 Cr | 4.35 Cr | 0.3363 | 1.79 Cr | 1.40 Cr | 1.89 | 1.94 Cr | 0.1086 |
| 2025-06-30 | 10.85 Cr | 4.42 Cr | 6.43 Cr | 0.5927 | -0.12 Cr | -0.04 Cr | -0.06 | 0.07 Cr | -0.0040 |
| 2025-03-31 | 12.32 Cr | 5.51 Cr | 6.82 Cr | 0.5531 | 0.95 Cr | -3.39 Cr | -4.58 | 1.14 Cr | -0.2752 |
| 2024-12-31 | 12.68 Cr | 4.48 Cr | 8.20 Cr | 0.6466 | 1.00 Cr | 1.01 Cr | 1.36 | 1.16 Cr | 0.0795 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.36 Cr | 2.62 Cr | 2.99 Cr | 6.53 Cr | 3.46 Cr | 14.30 Cr | 3.47 Cr | 24.43 Cr | 16.59 Cr |
| 2025-03-31 | 0.78 Cr | 1.01 Cr | 1.29 Cr | 5.24 Cr | 3.68 Cr | 12.02 Cr | 3.65 Cr | 22.83 Cr | 16.35 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -8.86 Cr |
| 2024-09-30 | 0.09 Cr | 0.00 Cr | 0.09 Cr | 7.90 Cr | 3.76 Cr | 13.13 Cr | 3.68 Cr | 24.84 Cr | 15.98 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7.11 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -3.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1.01 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -0.08 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 0.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹830.35 | ₹99,644,807,413.00 | ₹76,499.00 |
Key Executives
Gender: Not Specified
Year Born: 1987
Gender: Not Specified
Year Born: 1974
Gender: Not Specified
Year Born: 1979
Gender: Not Specified
Year Born: 1975
Gender: male
Year Born: 1988
Gender: male
Year Born: 1954
Gender: male
Year Born: 1977
Gender: male
Year Born: 1952
Gender: female
Year Born:
Gender: Not Specified
Year Born: 1972
FAQs about Gujarat Terce Laboratories Limited
The CEO is Aalap Natubhai Prajapati.
The current price is ₹39.95.
The range is ₹37.2-76.89.
The market capitalization is ₹31.13 crores.
The P/E ratio is -24.51.
The company operates in the Healthcare sector.
Overview of Gujarat Terce Laboratories Limited (ISIN: INE499G01013) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹31.13 crores and an average daily volume of 3,534 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.